<p>Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives</p>-Reference-Cited by-同舟云学术

Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives

Published:2020-07 Issue: Volume:Volume 12 Page:97-108
ISSN:1179-1438
Container-title:Clinical Pharmacology: Advances and Applications
language:en
Short-container-title:CPAA

Author:

Zulfikar Sabrina,Mulholland Sarah,Adamali Huzaifa^ORCID,Barratt Shaney L

Publisher

Informa UK Limited

Subject

Pharmacology (medical)

Reference85 articles.

1. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

2. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

3. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

4. NICE clinical guideline CG 163: idiopathic pulmonary fibrosis in adults: diagnosis and management. 2013. Available from: www.nice.org.uk. Accessed June 5 2018.

5. Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease;Inflammation and Regeneration;2024-07-19

2. Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives;Multidisciplinary Respiratory Medicine;2024-06-13

3. Lysophosphatidic acid and itsreceptors: Role in bronchial asthma pathogenesis;Acta Biomedica Scientifica;2024-03-25

4. Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis;Expert Opinion on Investigational Drugs;2024-02

5. Reply to: “Dysregulation of the LPC-ATX-LPA axis in autoimmune hepatitis is associated with monocyte activation”;Journal of Hepatology;2024-01